🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Proteinopathies Expression in Skin of Neurodegenerative Disorders

Recruitingn/aAges 45 Years - anyAllUniversidad Autonoma de San Luis Potosí
NCT06528964 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is: * Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects? Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative d

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria for patients: * Patients 45 years and older * Men and women * Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus * Patients that voluntarily accept to participate in the study and accept the consent form Inclusion Criteria healthy control subjects: * People 45 years and older * Men and women * Subjects can be related to a patient but not by blood (for example spouse of a patient) * Subjects don't have direct family history of a neurodegenerative control * Subjects don't have any clinical findings suggesting dementia * Subjects voluntarily accept to participate in the study and accept the consent form Exclusion Criteria: * Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia * Patients in which the diagnosis is not clear or hasn't been confirmed * Patients or controls that have a neuroinfection * Patients or controls that a diagnosed skin disease * Patients that have an "atypical" presentation of the disease * Patients or controls that have diagnosis of a coagulopathy
💊

What it tests

  • Immunohistochemistry and immunofluorescence
📍

Where

1 site
Hospital Central Dr. Ignacio Morones Prieto
San Luis Potosí City, Mexico
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy